top of page
Recruiting

NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Cilta-Cel CART

Updated: Feb 6

NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel


 A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

CART


The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.


Sponsor

 

ClinicalTrials.gov Identifier: NCT05201781

Official Title: Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel

First Posted : January 21, 2022

Click here for details on ClinicalTrials.gov

 

CART

JNJ-68284528

Ciltacabtagene Autoleucel

 

Drug: Cilta-cel

 

Locations

United States, Arizona

United States, California

United States, Illinois

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, New Jersey

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, Tennessee

United States, Wisconsin

Europe

Asia

Belgium

Spain

China

Israel

Japan

 

RELATED POSTS


NCT03548207: CARTITUDE-1 - Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in RRMM

A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma


NCT04133636: CARTITUDE-2 - Phase 2 study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma


NCT04181827: CARTITUDE 4 - Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relapsed len ref RRMM

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma


NCT04923893: CARTITUDE-5 - Phase 3 - VRd f/by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned)

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy


NCT05257083: CARTITUDE-6 - Phase 3: EMN 28 - DVRd -> Cilta-Cel (CART) Vs DVRd -> Transplant ASCT NDMM

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

Posts Archive
bottom of page